Quoin Pharmaceuticals, Ltd. financial data

Symbol
QNRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
23 Hata'as Street, Kfar Saba, Israel
State of incorporation
Israel
Former names
Cellect Biotechnology Ltd. (to 10/15/2021), Cellect Biomed Ltd. (to 7/7/2016)
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 341 % -2.55%
Debt-to-equity 83.3 % -6.12%
Return On Equity -115 % -9.16%
Return On Assets -62.6 % -12.4%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 8.95M shares +806%
Entity Public Float 2.3M USD -60.3%
Common Stock, Value, Issued 0 USD

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.6M USD +8.91%
Nonoperating Income (Expense) 566K USD -18.2%
Net Income (Loss) Attributable to Parent -8.96M USD -3.18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.62M USD +50.9%
Assets, Current 14.9M USD +32.3%
Intangible Assets, Net (Excluding Goodwill) 483K USD -17.1%
Assets 15.7M USD +29.1%
Accounts Payable, Current 906K USD +72%
Accrued Liabilities, Current 1.53M USD +16.8%
Liabilities, Current 4.18M USD +16.7%
Other Liabilities, Noncurrent 2.32M USD -20.5%
Liabilities 6.5M USD -0.01%
Accumulated Other Comprehensive Income (Loss), Net of Tax 55.2M USD +19.5%
Retained Earnings (Accumulated Deficit) -55.2M USD -19.4%
Stockholders' Equity Attributable to Parent 9.2M USD +62.5%
Liabilities and Equity 15.7M USD +29.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.43M USD +17.9%
Net Cash Provided by (Used in) Financing Activities 5.33M USD -7.25%
Net Cash Provided by (Used in) Investing Activities -4.47M USD -27.9%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 8.95M shares +806%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.62M USD +50.9%
Deferred Tax Assets, Valuation Allowance 8.47M USD +36.2%
Deferred Tax Assets, Gross 8.47M USD +36.2%
Deferred Tax Assets, Operating Loss Carryforwards 5.68M USD +32.9%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 64.4M USD +24.1%
Amortization of Intangible Assets 100K USD -3.57%
Share-based Payment Arrangement, Expense 1.26M USD +15.6%